Table 2.
Summary of the case report and case series findings.
| Variables |
Number of studies |
n/N* | % | |
|---|---|---|---|---|
| Comorbidities | Hypertension | 22 | 44/228 | 19 |
| Cardiovascular disease | 6 | 11/137 | 8 | |
| Diabetes | 17 | 27/241 | 11 | |
| Pulmonary disease | 8 | 13/107 | 12 | |
| Clinical manifestations | Fever | 68 | 248/401 | 62 |
| Cough | 39 | 195/389 | 50 | |
| Dyspnea | 30 | 78/279 | 28 | |
| Myalgia/fatigue | 38 | 106/343 | 31 | |
| Sputum production | 14 | 49/197 | 25 | |
| Sore throat | 20 | 48/164 | 29 | |
| Headache | 11 | 37/149 | 25 | |
| Diarrhea | 14 | 21/94 | 22 | |
| Nausea/vomiting | 8 | 17/84 | 20 | |
| Dizziness | 5 | 5/35 | 14 | |
| Rhinorrhea | 13 | 22/196 | 11 | |
| Chills | 4 | 4/13 | 31 | |
| Laboratory findings | Lymphopenia | 24 | 83/185 | 45 |
| Leukopenia | 17 | 38/150 | 25 | |
| Thrombocytopenia | 8 | 26/69 | 38 | |
| High CRP | 18 | 118/197 | 60 | |
| High LDH | 14 | 34/77 | 44 | |
| High ESR | 10 | 17/42 | 40 | |
| High AST | 11 | 23/48 | 48 | |
| High ALT | 13 | 22/77 | 28.5 | |
| High creatinine kinase | 8 | 9/44 | 20 | |
| High creatinine | 4 | 6/32 | 19 | |
| CT | Both of GGO and Consolidation | 16 | 32/59 | 54 |
| GGO without consolidation | 20 | 48/60 | 80 | |
| Unilateral | 11 | 35/87 | 40 | |
| Bi lateral | 23 | 76/110 | 69 | |
| Complications | ARDS | 11 | 18/86 | 21 |
| Hospitalization | 30 | 77/83 | 93 | |
| Outcomes | Discharged | 23 | 137/205 | 67 |
| Death | 10 | 17/108 | 16 |
*
n, number of patients with any variables; N, the total number of patients with COVID-19.